Thymosin β4 expression correlates with lymph node metastasis through hypoxia inducible factor-α induction in breast cancer

Oncology Reports

Volumn 25, Issue 1, 2011, Pages 23-31

  Yoon, Sun Young ^a   Lee, Ha Reum ^a   Park, Yoorim ^a   Kim, Joo Heon ^b   Kim, Soo Young ^c   Yoon, Suk Ran ^d   Lee, Wang Jae ^e   Cho, Byung Joo ^f   Min, Hyeyoung ^g   Bang, Jung Wook ^j   Park, Hyunjeong ^h   Bang, Sa Ik ⁱ   Cho, Daeho ^a  

^a Sookmyung Women's University   (South Korea)

^b Eulji University   (South Korea)

^c Eulji University School of Medicine   (South Korea)

^d Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^e Seoul National University College of Medicine   (South Korea)

^f Konkuk University Hospital   (South Korea)

^g Chung Ang University   (South Korea)

^h The Catholic University of Korea   (South Korea)

ⁱ Sungkyunkwan University   (South Korea)

^j IMPERIAL COLLEGE LONDON   (United Kingdom)

more..

Author keywords

Breast carcinoma; HIF ; Lymph node metastasis; Thymosin 4; VEGF A

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; LENTIVIRUS VECTOR; PROGESTERONE RECEPTOR; PROTEIN P53; SHORT HAIRPIN RNA; THYMOSIN BETA4; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN C; VASCULOTROPIN D;

ADULT; AGE DISTRIBUTION; ARTICLE; BREAST CARCINOMA; CANCER SIZE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; GENE OVEREXPRESSION; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; LYMPHANGIOGENESIS; METASTASIS POTENTIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; UPREGULATION;

BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL HYPOXIA; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THYMOSIN; TUMOR MARKERS, BIOLOGICAL;

EID: 78650742217     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or-00001037     Document Type: Article

References (50)

1. Vaupel P, Kallinowski F and Okunieff P: Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 49: 6449-6465, 1989.
2. Semenza GL and Wang GL: A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 12: 5447-5454, 1992.
3. Hockel M and Vaupel P: Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 93: 266-276, 2001.
4. Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U and Vaupel P: Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 56: 4509-4515, 1996.
5. Hockel M, Schlenger K, Hockel S and Vaupel P: Hypoxic cervical cancers with low apoptotic index are highly aggressive. Cancer Res 59: 4525-4528, 1999.
6. Wang GL, Jiang BH, Rue EA and Semenza GL: Hypoxiainducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 92: 5510-5514, 1995.
7. Semenza GL: Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol 15: 551-578, 1999.
8. Brahimi-Horn MC and Pouyssegur J: HIF at a glance. J Cell Sci 122: 1055-1057, 2009.
9. Schofield CJ and Ratcliffe PJ: Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol 5: 343-354, 2004.
10. Salceda S and Caro J: Hypoxia-inducible factor 1alpha (HIF-1 alpha) protein is rapidly degraded by the ubiquitinproteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J Biol Chem 272: 22642-22647, 1997.
11. Huang LE, Gu J, Schau M and Bunn HF: Regulation of hypoxiainducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA 95: 7987-7992, 1998.
12. Liao D, Corle C, Seagroves TN and Johnson RS: Hypoxiainducible factor-1alpha is a key regulator of metastasis in a transgenic model of cancer initiation and progression. Cancer Res 67: 563-572, 2007.
13. Yamamoto Y, Ibusuki M, Okumura Y, et al: Hypoxia-inducible factor 1alpha is closely linked to an aggressive phenotype in breast cancer. Breast Cancer Res Treat 110: 465-475, 2008.
14. Giatromanolaki A, Sivridis E, Fiska A and Koukourakis MI: Hypoxia-inducible factor-2 alpha (HIF-2 alpha) induces angiogenesis in breast carcinomas. Appl Immunohistochem Mol Morphol 14: 78-82, 2006.
15. Helczynska K, Larsson AM, Holmquist Mengelbier L, et al: Hypoxia-inducible factor-2alpha correlates to distant recurrence and poor outcome in invasive breast cancer. Cancer Res 68: 9212-9220, 2008
16. Semenza GL: Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3: 721-732, 2003.
17. Harris AL: Hypoxia, a key regulatory factor in tumour growth. Nat Rev Cancer 2: 38-47, 2002.
18. Brahimi-Horn MC, Chiche J and Pouyssegur J: Hypoxia and cancer. J Mol Med 85: 1301-1307, 2007.
19. Brahimi-Horn MC, Chiche J and Pouyssegur J: Hypoxia signalling controls metabolic demand. Curr Opin Cell Biol 19: 223-229, 2007.
20. Neufeld G, Cohen T, Gengrinovitch S and Poltorak Z: Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 13: 9-22, 1999.
21. Hirakawa S, Kodama S, Kunstfeld R, Kajiya K, Brown LF and Detmar M: VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis. J Exp Med 201: 1089-1099, 2005.
22. Halin C, Tobler NE, Vigl B, Brown LF and Detmar M: VEGF-A produced by chronically inflamed tissue induces lymphangiogenesis in draining lymph nodes. Blood 110: 3158-3167, 2007.
23. Ballweber E, Hannappel E, Huff T, et al: Polymerisation of chemically cross-linked actin:thymosin betaβ4) complex to filamentous actin: alteration in helical parameters and visualisation of thymosin betaβ4) binding on F-actin. J Mol Biol 315: 613-625, 2002.
24. Sanders MC, Goldstein AL and Wang YL: Thymosin beta 4 (Fx peptide) is a potent regulator of actin polymerization in living cells. Proc Natl Acad Sci USA 89: 4678-4682, 1992.
25. Cha HJ, Jeong MJ and Kleinman HK: Role of thymosin beta4 in tumor metastasis and angiogenesis. J Natl Cancer Inst 95: 1674-1680, 2003.
26. Koutrafouri V, Leondiadis L, Avgoustakis K, et al: Effect of thymosin peptides on the chick chorioallantoic membrane angiogenesis model. Biochim Biophys Acta 1568: 60-66, 2001.
27. Malinda KM, Sidhu GS, Mani H, et al: Thymosin beta4 accelerates wound healing. J Invest Dermatol 113: 364-368, 1999.
28. Philp D, Badamchian M, Scheremeta B, Nguyen M, Goldstein AL and Kleinman HK: Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice. Wound Repair Regen 11: 19-24, 2003.
29. Badamchian M, Fagarasan MO, Danner RL, Suffredini AF, Damavandy H and Goldstein AL: Thymosin betaβ4) reduces lethality and down-regulates inflammatory mediators in endotoxin-induced septic shock. Int Immunopharmacol 3: 1225-1233, 2003.
30. Sosne G, Szliter EA, Barrett R, Kernacki KA, Kleinman H and Hazlett LD: Thymosin beta 4 promotes corneal wound healing and decreases inflammation in vivo following alkali injury. Exp Eye Res 74: 293-299, 2002.
31. Young JD, Lawrence AJ, MacLean AG, et al: Thymosin beta 4 sulfoxide is an anti-inflammatory agent generated by monocytes in the presence of glucocorticoids. Nat Med 5: 1424-1427, 1999.
32. Bock-Marquette I, Saxena A, White MD, Dimaio JM and Srivastava D: Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature 432: 466-472, 2004.
33. Wang WS, Chen PM, Hsiao HL, Ju SY and Su Y: Overexpression of the thymosin beta-4 gene is associated with malignant progression of SW480 colon cancer cells. Oncogene 22: 3297-3306, 2003.
34. Wang WS, Chen PM, Hsiao HL, Wang HS, Liang WY and Su Y: Overexpression of the thymosin beta-4 gene is associated with increased invasion of SW480 colon carcinoma cells and the distant metastasis of human colorectal carcinoma. Oncogene 23: 6666-6671, 2004.
35. Huang HC, Hu CH, Tang MC, Wang WS, Chen PM and Su Y: Thymosin beta4 triggers an epithelial-mesenchymal transition in colorectal carcinoma by upregulating integrin-linked kinase. Oncogene 26: 2781-2790, 2007.
36. Wittekind C, Compton CC, Greene FL and Sobin LH: TNM residual tumor classification revisited. Cancer 94: 2511-2516, 2002.
37. Boden D, Pusch O, Silbermann R, Lee F, Tucker L and Ramratnam B: Enhanced gene silencing of HIV-1 specific siRNA using microRNA designed hairpins. Nucleic Acids Res 32: 1154-1158, 2004.
38. Dull T, Zufferey R, Kelly M, et al: A third-generation lentivirus vector with a conditional packaging system. J Virol 72: 8463-8471, 1998.
39. Follenzi A, Ailles LE, Bakovic S, Geuna M and Naldini L: Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nat Genet 25: 217-222, 2000.
40. Oh JM, Ryoo IJ, Yang Y, Kim HS, Yang KH and Moon EY: Hypoxia-inducible transcription factor (HIF)-1 alpha stabilization by actin-sequestering protein, thymosin beta-4 (TB4) in Hela cervical tumor cells. Cancer Lett 264: 29-35, 2008.
41. Schoppmann SF, Fenzl A, Schindl M, et al: Hypoxia inducible factor-1alpha correlates with VEGF-C expression and lymphangiogenesis in breast cancer. Breast Cancer Res Treat 99: 135-141, 2006.
42. Achen MG and Stacker SA: Molecular control of lymphatic metastasis. Ann N Y Acad Sci 1131: 225-234, 2008.
43. Eccles S, Paon L and Sleeman J: Lymphatic metastasis in breast cancer: importance and new insights into cellular and molecular mechanisms. Clin Exp Metastasis 24: 619-636, 2007.
44. Kimbro KS and Simons JW: Hypoxia-inducible factor-1 in human breast and prostate cancer. Endocr Relat Cancer 13: 739-749, 2006.
45. Yamamoto T, Gotoh M, Kitajima M and Hirohashi S: Thymosin beta-4 expression is correlated with metastatic capacity of colorectal carcinomas. Biochem Biophys Res Commun 193: 706-710, 1993.
46. Larsson LI and Holck S: Occurrence of thymosin beta4 in human breast cancer cells and in other cell types of the tumor microenvironment. Hum Pathol 38: 114-119, 2007.
47. Cao R, Bjorndahl MA, Religa P, et al: PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic metastasis. Cancer Cell 6: 333-345, 2004.
48. Whitehurst B, Flister MJ, Bagaitkar J, et al: Anti-VEGF-A therapy reduces lymphatic vessel density and expression of VEGFR-3 in an orthotopic breast tumor model. Int J Cancer 121: 2181-2191, 2007.
49. Kajiya K, Hirakawa S, Ma B, Drinnenberg I and Detmar M: Hepatocyte growth factor promotes lymphatic vessel formation and function. EMBO J 24: 2885-2895, 2005.
50. van der Schaft DW, Pauwels P, Hulsmans S, Zimmermann M, van de Poll-Franse LV and Griffioen AW: Absence of lymphangiogenesis in ductal breast cancer at the primary tumor site. Cancer Lett 254: 128-136, 2007